A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy

Pharmacological Research

Volumn 61, Issue 5, 2010, Pages 419-429

  Eisenstein, Sarah A ^a   Clapper, Jason R ^b   Holmes, Philip V ^a   Piomelli, Daniele ^b,c   Hohmann, Andrea G ^a  

^a University of Georgia ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

2 AG; 2 Arachidonoylglycerol; Endocannabinoid; Locomotor response; Novelty; Olfactory bulbectomy

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; ENDOCANNABINOID; RIMONABANT;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; CORPUS STRIATUM; DENSITOMETRY; HABITUATION; LIQUID CHROMATOGRAPHY; LOCOMOTION; MALE; MASS SPECTROMETRY; NONHUMAN; OLFACTORY BULBECTOMY; OPEN FIELD TEST; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; RECEPTOR DENSITY;

ANIMALS; ARACHIDONIC ACIDS; AUTORADIOGRAPHY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANOLS; DENSITOMETRY; DOPAMINE; ENDOCANNABINOIDS; ENVIRONMENT; GLYCERIDES; LIMBIC SYSTEM; LIPID METABOLISM; MALE; MASS SPECTROMETRY; MOTOR ACTIVITY; OLFACTORY BULB; PIPERIDINES; PYRAZOLES; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION;

EID: 77950628341     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.12.013     Document Type: Article

References (69)

1. Pacher P., Batkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006, 58:389-462.
2. Thakur G.A., Tichkule R., Bajaj S., Makriyannis A. Latest advances in cannabinoid receptor agonists. Expert Opin Ther Pat 2009, 19:1647-1673.
3. Di Marzo V., Bifulco M., De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004, 3:771-784.
4. Howlett A.C. Cannabinoid receptor signaling. Handb Exp Pharmacol 2005, 53-79.
5. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 1992, 89:3825-3829.
6. Mackie K., Lai Y., Westenbroek R., Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 1995, 15:6552-6561.
7. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994, 372:686-691.
8. Piomelli D. The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 2005, 6:672-679.
9. Kreitzer A.C., Regehr W.G. Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J Neurosci 2001, 21:RC174.
10. Ohno-Shosaku T., Maejima T., Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001, 29:729-738.
11. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001, 410:588-592.
12. Katona I., Freund T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med 2008, 14:923-930.
13. Mora F., Segovia G., Del Arco A. Glutamate-dopamine-GABA interactions in the aging basal ganglia. Brain Res Rev 2008, 58:340-353.
14. Spanagel R., Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci 1999, 22:521-527.
15. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991, 11:563-583.
16. Hohmann A.G., Herkenham M. Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse 2000, 37:71-80.
17. Uchigashima M., Narushima M., Fukaya M., Katona I., Kano M., Watanabe M. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci 2007, 27:3663-3676.
18. Kofalvi A., Rodrigues R.J., Ledent C., Mackie K., Vizi E.S., Cunha R.A., et al. Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci 2005, 25:2874-2884.
19. Patel S., Rademacher D.J., Hillard C.J. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J Pharmacol Exp Ther 2003, 306:880-888.
20. Gilad G.M., Reis D.J. Collateral sprouting in central mesolimbic dopamine neurons: biochemical and immunocytochemical evidence of changes in the activity and distribution of tyrosine hydroxylase in terminal fields and in cell bodies of A10 neurons. Brain Res 1979, 160:17-26.
21. Lingham R.B., Gottesfeld Z. Deafferentation elicits increased dopamine-sensitive adenylate cyclase and receptor binding in the olfactory tubercle. J Neurosci 1986, 6:2208-2214.
22. Chambers R.A., Sheehan T., Taylor J.R. Locomotor sensitization to cocaine in rats with olfactory bulbectomy. Synapse 2004, 52:167-175.
23. Masini C.V., Holmes P.V., Freeman K.G., Maki A.C., Edwards G.L. Dopamine overflow is increased in olfactory bulbectomized rats: an in vivo microdialysis study. Physiol Behav 2004, 81:111-119.
24. Eisenstein S.A., Holmes P.V., Hohmann A.G. Endocannabinoid modulation of amphetamine sensitization is disrupted in a rodent model of lesion-induced dopamine dysregulation. Synapse 2009, 63:941-950.
25. Kelly J.P., Wrynn A.S., Leonard B.E. The olfactory bulbectomized rat as a model of depression: an update. Pharmacol Ther 1997, 74:299-316.
26. Primeaux S.D., Wilson M.A., Wilson S.P., Guth A.N., Lelutiu N.B., Holmes P.V. Herpes virus-mediated preproenkephalin gene transfer in the ventral striatum mimics behavioral changes produced by olfactory bulbectomy in rats. Brain Res 2003, 988:43-55.
27. Song C., Leonard B.E. The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 2005, 29:627-647.
28. Klein D., Brown T.S. Exploratory behavior and spontaneous alternation in blind and anosmic rats. J Comp Physiol Psychol 1969, 68:107-110.
29. van Riezen H., Leonard B.E. Effects of psychotropic drugs on the behavior and neurochemistry of olfactory bulbectomized rats. Pharmacol Ther 1990, 47:21-34.
30. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 2005, 313:352-358.
31. Patel S., Hillard C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006, 318:304-311.
32. Jarbe T.U., Andrzejewski M.E., DiPatrizio N.V. Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol Biochem Behav 2002, 73:911-919.
33. Paxinos G., Watson C. The rat brain in stereotaxic coordinates, vol. 1 1998, Academic Press, San Diego, (unpaged). 4th ed.
34. Astarita G., Piomelli D. Lipidomic analysis of endocannabinoid metabolism in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:2755-2767.
35. Hohmann A.G., Briley E.M., Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 1999, 822:17-25.
36. Hohmann A.G., Herkenham M. Regulation of cannabinoid and mu opioid receptors in rat lumbar spinal cord following neonatal capsaicin treatment. Neurosci Lett 1998, 252:13-16.
37. Saigusa T., Tuinstra T., Koshikawa N., Cools A.R. High and low responders to novelty: effects of a catecholamine synthesis inhibitor on novelty-induced changes in behaviour and release of accumbal dopamine. Neuroscience 1999, 88:1153-1163.
38. Verheij M.M., de Mulder E.L., De Leonibus E., van Loo K.M., Cools A.R. Rats that differentially respond to cocaine differ in their dopaminergic storage capacity of the nucleus accumbens. J Neurochem 2008, 105:2122-2133.
39. Holmes P.V. Olfactory bulbectomy increases prepro-enkephalin mRNA levels in the ventral striatum in rats. Neuropeptides 1999, 33:206-211.
40. Mar A., Spreekmeester E., Rochford J. Antidepressants preferentially enhance habituation to novelty in the olfactory bulbectomized rat. Psychopharmacology (Berl) 2000, 150:52-60.
41. Mar A., Spreekmeester E., Rochford J. Fluoxetine-induced increases in open-field habituation in the olfactory bulbectomized rat depend on test aversiveness but not on anxiety. Pharmacol Biochem Behav 2002, 73:703-712.
42. Holmes P.V. Rodent models of depression: reexamining validity without anthropomorphic inference. Crit Rev Neurobiol 2003, 15:143-174.
43. Adamczyk P., Golda A., McCreary A.C., Filip M., Przegalinski E. Activation of endocannabinoid transmission induces antidepressant-like effects in rats. J Physiol Pharmacol 2008, 59:217-228.
44. Bortolato M., Mangieri R.A., Fu J., Kim J.H., Arguello O., Duranti A., et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 2007, 62:1103-1110.
45. Hill M.N., Barr A.M., Ho W.S., Carrier E.J., Gorzalka B.B., Hillard C.J. Electroconvulsive shock treatment differentially modulates cortical and subcortical endocannabinoid activity. J Neurochem 2007, 103:47-56.
46. Hill M.N., Carrier E.J., McLaughlin R.J., Morrish A.C., Meier S.E., Hillard C.J., et al. Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 2008, 106:2322-2336.
47. Maccarrone M., Valverde O., Barbaccia M.L., Castane A., Maldonado R., Ledent C., et al. Age-related changes of anandamide metabolism in CB1 cannabinoid receptor knockout mice: correlation with behaviour. Eur J Neurosci 2002, 15:1178-1186.
48. Rodriguez-Gaztelumendi A., Rojo M.L., Pazos A., Diaz A. Altered CB receptor-signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine. J Neurochem 2009, 108:1423-1433.
49. Jung K.M., Mangieri R., Stapleton C., Kim J., Fegley D., Wallace M., et al. Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. Mol Pharmacol 2005, 68:1196-1202.
50. Adermark L., Talani G., Lovinger D.M. Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity. Eur J Neurosci 2009, 29:32-41.
51. Kreitzer A.C., Malenka R.C. Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci 2005, 25:10537-10545.
52. Lafenetre P., Chaouloff F., Marsicano G. Bidirectional regulation of novelty-induced behavioral inhibition by the endocannabinoid system. Neuropharmacology 2009, 57:715-721.
53. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Meozzi P.A., Myers L., et al. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann NY Acad Sci 2008, 1139:434-449.
54. Ho Y.J., Chang Y.C., Liu T.M., Tai M.Y., Wong C.S., Tsai Y.F. Striatal glutamate release during novelty exposure-induced hyperactivity in olfactory bulbectomized rats. Neurosci Lett 2000, 287:117-120.
55. Navarro M., Hernandez E., Munoz R.M., del Arco I., Villanua M.A., Carrera M.R., et al. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716a induces anxiety-like responses in the rat. Neuroreport 1997, 8:491-496.
56. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., et al. SR141716a, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994, 350:240-244.
57. Haller J., Bakos N., Szirmay M., Ledent C., Freund T.F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 2002, 16:1395-1398.
58. Haller J., Varga B., Ledent C., Barna I., Freund T.F. Context-dependent effects of CB1 cannabinoid gene disruption on anxiety-like and social behaviour in mice. Eur J Neurosci 2004, 19:1906-1912.
59. Haller J., Varga B., Ledent C., Freund T.F. CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav Pharmacol 2004, 15:299-304.
60. Arevalo C., de Miguel R., Hernandez-Tristan R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacol Biochem Behav 2001, 70:123-131.
61. Pertwee R.G. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005, 76:1307-1324.
62. Kapur A., Zhao P., Sharir H., Bai Y., Caron M.G., Barak L.S., et al. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J Biol Chem 2009, 284:29817-29827.
63. Sawzdargo M., Nguyen T., Lee D.K., Lynch K.R., Cheng R., Heng H.H., et al. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 1999, 64:193-198.
64. Thiemann G., Di Marzo V., Molleman A., Hasenohrl R.U. The CB(1) cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus. Pharmacol Biochem Behav 2008, 89:384-391.
65. Thiemann G., van der Stelt M., Petrosino S., Molleman A., Di Marzo V., Hasenohrl R.U. The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization. Behav Brain Res 2008, 187:289-296.
66. Gorzalka B.B., Hill M.N., Hillard C.J. Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. Neurosci Biobehav Rev 2008, 32:1152-1160.
67. Haller J., Barna I., Barsvari B., Gyimesi Pelczer K., Yasar S., Panlilio L.V., et al. Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology (Berl) 2009, 204:607-616.
68. Sil'kis I.G. The role of dopamine-dependent negative feedback in the hippocampus-basal ganglia-thalamus-hippocampus loop in the extinction of responses. Neurosci Behav Physiol 2008, 38:399-405.
69. Paxinos G., Watson C. The rat brain in stereotaxic coordinates, vol. 1 2005, Elsevier Academic Press, Boston, (unpaged). 5th ed.